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Systematic Review
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Brian K. Kwon, MD, PhD5, Steve Casha, MD, PhD, FRCSC6, Katherine Palmieri, MD1,
Jefferson R. Wilson, MD, PhD7,8, Michael G. Fehlings, MD, PhD, FRCSC, FACS4,
Haley K. Holmer, MPH9, and Daniel C. Norvell, PhD, MPH9
Abstract
Study Design: Systematic review.
Objectives: The objective of this study was to answer 5 key questions: What is the comparative effectiveness and safety of (1a)
anticoagulant thromboprophylaxis compared to no prophylaxis, placebo, or another anticoagulant strategy for preventing deep
vein thrombosis (DVT) and pulmonary embolism (PE) after acute spinal cord injury (SCI)? (1b) Mechanical prophylaxis strategies
alone or in combination with other strategies for preventing DVT and PE after acute SCI? (1c) Prophylactic inferior vena cava filter
insertion alone or in combination with other strategies for preventing DVT and PE after acute SCI? (2) What is the optimal timing
to initiate and/or discontinue anticoagulant, mechanical, and/or prophylactic inferior vena cava filter following acute SCI? (3) What
is the cost-effectiveness of these treatment options?
Methods: A systematic literature search was conducted to identify studies published through February 28, 2015. We sought
randomized controlled trials evaluating efficacy and safety of antithrombotic strategies. Strength of evidence was evaluated using
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.
Results:Nine studies satisfied inclusion criteria.We found a trend toward lower risk ofDVT in patients treatedwith enoxaparin. There
were no significant differences in rates of DVT, PE, bleeding, and mortality between patients treated with different types of low-
molecular-weight heparin or between low-molecular-weight heparin and unfractionated heparin. Combined anticoagulant and
mechanical prophylaxis initiatedwithin 72hoursof SCI resulted in lower risk ofDVT than treatment commenced after 72 hours of injury.
Conclusion: Prophylactic treatments can be used to lower the risk of venous thromboembolic events in patients with acute SCI,
without significant increase in risk of bleeding and mortality and should be initiated within 72 hours.
Keywords
deep vein thrombosis, pulmonary embolism, spinal cord injury, bleeding, mortality
Introduction
Patients with spinal cord injury (SCI) are at an increased risk of
venous thromboembolic (VTE) events due to hypercoagulabil-
ity, stasis, and intimal injury.1 Interruption of neurologic
impulses and paralysis cause metabolic changes to the blood
vessels and altered venous competence such as decreased dis-
tensibility and increased flow resistance.2 Furthermore, immo-
bilization of the lower extremities results in stagnant blood
flow and ultimately the formation of venous thrombi. Patients
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with SCI often require complex spinal surgical procedures to
decompress and stabilize their spine and, as a result, are often
immobilized for several hours and subjected to further tissue
and vessel damage.
VTE is a significant cause of morbidity and mortality in SCI
patients and includes both deep vein thrombosis (DVT) and
pulmonary embolism (PE).1 Venous thrombi most commonly
form in the lower extremities; here they remain as chronic
venous abnormalities, undergo endogenous fibrinolysis and
recanalization, or propagate and embolize to the pulmonary
system. Obstruction of the pulmonary arteries may lead to a
number of life-threatening physiologic changes, including
impaired gas exchange, cardiovascular compromise, and
right-sided heart failure.
The prevention of DVT and PE is critical in this high-risk
population. Prophylactic treatment with anticoagulants and
other mechanical strategies may significantly reduce the risk
of VTE events in these patients. There may be significant risks
to anticoagulant thromboprophylaxis in trauma patients,
including symptomatic hematoma formation, enlargement of
a spinal cord contusion, worsening of neurologic deficits,
bleeding, and mortality.3,4
The objective of this study was to conduct a systematic
review to address the following key questions:
In adult patients with acute complete or incomplete trau-
matic SCI,
Key Question 1: What is the effectiveness and safety of
anticoagulant thromboprophylaxis compared to no prophy-
laxis, placebo, or another anticoagulant strategy for prevent-
ing DVT and PE after acute SCI?
Key Question 2:What is the comparative effectiveness and
safety of mechanical prophylaxis strategies alone or in com-
bination with other prophylactic strategies for preventing
DVT and PE after acute SCI?
Key Question 3:What is the comparative effectiveness and
safety of prophylactic inferior vena cava (IVC) filter inser-
tion alone or in combination with other prophylactic strate-
gies for preventing DVT and PE after acute SCI?
Key Question 4:What is the optimal timing to initiate and/
or discontinue anticoagulant, mechanical, and/or prophylac-
tic IVC filter following acute SCI?
Key Question 5:What is the cost-effectiveness of the treat-
ment options mentioned above?
Materials and Methods
Electronic Literature Search
A systematic search of the literature was performed to identify
potential studies published through February 28, 2015. Studies
in all languages were considered for inclusion. The MEDLINE
database was searched using the PubMed interface to identify
primary studies and systematic reviews. The Cochrane Colla-
boration Library and bibliographies of relevant articles were
also searched. We focused on studies designed to evaluate the
efficacy/effectiveness and safety of pharmacological, mechan-
ical, and/or prophylactic IVC filter in adults with complete or
incomplete acute SCI. Specifically, we sought studies that
reported the risks of PE, DVT, bleeding, mortality, and other
adverse events following prophylactic treatment. In addition,
we searched for studies that examined the optimal timing to
initiate and discontinue prophylaxis.
The search strategies are described in the Supplemental
Material (available in the online version of the article) and
included use of controlled vocabulary (MeSH terms) as well
as keywords. For all key questions, terms for anticoagulation
were combined with terms specifying SCI. Additional terms
for timing were added to the search strategy for Key Question
4 (Supplemental Material). For Key Questions 1, 2, and 3, we
focused on randomized controlled trials (RCTs) that evalu-
ated pharmacological and mechanical prophylaxis, and/or
prophylactic IVC filters. Since timing of an intervention is a
characteristic more likely observed than randomized, we
expanded our criteria for Key Question 4 to include all com-
parative studies. We excluded nonclinical studies, case series,
narrative reviews, abstracts/proceedings from meetings, white
papers, editorials, and studies with fewer than 10 subjects per
treatment arm. The PICO table provides a complete summary
of our inclusion/exclusion criteria (Table 1).
Study Selection and Data Abstraction
Studies were included if they examined either (1) the efficacy
and/or safety of anticoagulation prophylaxis or (2) the optimal
timing to initiate and/or discontinue prophylaxis in patients with
acute SCI. Two reviewers (JH and HH) independently identified
potential studies from the literature search. In instances of dis-
agreement regarding inclusion, a third reviewer (DN) was con-
sulted and consensus achieved through discussion. If an article
published in a foreign language appeared to meet inclusion cri-
teria based on the English abstract, we used Google Translate5 to
translate the entire article into English. If any part of the trans-
lation was unclear, we sought human translation assistance.
One reviewer (JH) used standardized forms to extract the
following data: age, sex, completeness and level of SCI, dose
and frequency of antithrombotic drugs, intervention character-
istics for mechanical and/or invasive prophylaxis, timing and
duration of prophylaxis, methods used to diagnose DVT and
PE, and results. A second reviewer checked the abstractions for
accuracy and completeness (HH).
Individual Study Quality
Two independent reviewers (HH and DN) critically appraised
each included study for risk of bias using criteria outlined by
The Journal of Bone & Joint Surgery, American Volume6 for
therapeutic studies and modified to encompass criteria associ-
ated with methodological quality7 (see the Supplemental Mate-
rial for individual study ratings; available in the online version
of the article). Disagreements in ratings were resolved through
discussion.
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Overall Strength of Body of Literature
After rating each individual article, the strength of the overall
body of evidence with respect to each outcome was deter-
mined based on precepts outlined by the Grading of Recom-
mendations Assessment, Development and Evaluation
(GRADE) Working Group8,9 and recommendations made by
the Agency for Healthcare Research and Quality
(AHRQ).10,11 Additional qualitative analysis was performed
according to AHRQ-required (risk of bias, consistency,
directness, precision) and additional domains (dose-
response, strength of association, publication bias).12 In gen-
eral, risk of bias was determined when evaluating each indi-
vidual article as described above.
Table 1. Inclusion and Exclusion Criteria.
Study
Component Inclusion Exclusion
Population Adults with traumatic acute spinal cord injury (complete or incomplete,
at any level)
 Pediatric patients
 Pregnancy
 Penetrating injuries to spinal cord
 Cord compression due to tumor, hematoma,
or degenerative disease (eg, CSM)
 Patients without neurological deficit
following trauma
Intervention KQ1: Any antithrombotic drug strategy
KQ2: Any mechanical strategy (intermittent pneumatic compression devices,
stockings, etc) used alone
KQ3: Prophylactic IVC filters used alone
KQ4: Any antithrombotic drug, mechanical, and/or prophylactic IVC filter
strategy initiated and/or discontinued at a specific timing
KQ5: Any interventions included in KQs 1-4
Comparators KQ1: Any other antithrombotic drug, placebo, or no prophylactic
intervention
KQ2: Any mechanical strategy (intermittent pneumatic compression devices,
stockings, etc) used alone or in combination with other prophylactic
strategies
KQ3: Prophylactic IVC filters used in combination with other prophylactic
strategies
KQ4: Same anticoagulant, mechanical (intermittent pneumatic compression
devices, stockings, etc), and/or prophylactic IVC filters initiated and/or
discontinued at another timing
KQ5: Any comparators included in KQs 1-4
Outcomes Efficacy/effectiveness
 Rate of deep venous thrombosis
 Rate of pulmonary embolism
Safety
 Bleeding
 Mortality
 Other adverse events
Cost-effectiveness
 Incremental cost-effectiveness ratio (or similar)
 Cost per unit of outcome
Study design KQs 1-3: Randomized controlled trials
KQ4: Randomized controlled trials and comparative non-randomized studies
KQ5: Full economic studies
 Animal studies
 Nonclinical studies
 Case series
 n < 10 per treatment arm
Publication  Studies with abstracts
 Published or translated into English in peer-reviewed journals
 Abstracts, editorials, letters
 Duplicate publications of the same study
which do not report on different outcomes
 Single-center reports from multicenter trials
 White papers
 Narrative reviews
 Proceedings/abstracts from meetings
 Articles identified as preliminary reports if
results are published in later versions
Abbreviations: CSM, cervical spondylotic myelopathy; IVC, inferior vena cava; KQ, key question.
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The initial strength of the overall body of evidence was con-
sidered “High” for RCTs and “Low” for observational studies.
The body of evidence could be downgraded 1 or 2 levels based
on the following criteria: (1) risk of bias (study limitations), (2)
inconsistency of results, (3) indirectness of evidence, (4) impre-
cision of the effect estimates (eg, wide confidence intervals), or
(4) failure to provide an a priori statement of subgroup analyses.
The body of evidence could be upgraded 1 or 2 levels based on
the following criteria: (1) large magnitude of effect or (2) dose-
response gradient or (3) if all plausible biases would decrease the
magnitude of an apparent effect.
The final overall strength of the body of literature expresses
(1) our confidence that the effect size lies close to the true
effect and (2) the extent to which the effect is believed to be
stable based on the adequacy of or deficiencies in the body of
evidence.9 An overall strength of “High” means that we are
very confident that the true effect lies close to that of the
estimated effect. A “Moderate” rating means that we are mod-
erately confident in the effect estimate; the true effect is likely
to be close to the estimated effect, but there is a possibility that
it is substantially different. An overall strength of “Low” means
that our confidence in the effect estimate is limited; the true
effect may be substantially different from the estimate. Finally,
a rating of “Insufficient” means that we have very little confi-
dence in the effect estimate; the true effect is likely to be
substantially different than the estimated effect. In addition,
this rating may be used if there is no evidence or it is not
possible to estimate an effect.
Analysis
When data was available, we calculated risk ratios (RRs) and
risk differences (RDs) with 95% confidence intervals (95% CIs)
to provide an estimate of effect size. Fisher exact test was used to
calculate P values due to the low number of events. P values
<.05 were considered statistically significant. Calculations were
performed using Stata 9.0.13 Pooling of data was performed if
studies were reasonably homogeneous with respect to patient
population, study quality, interventions, and outcome measures.
Results
The search yielded 282 citations. Four additional primary stud-
ies were identified from the bibliographies of other published
articles. Two hundred and sixty-nine citations were excluded
based on their title and/or abstract, while 17 were selected for
full-text investigation (Figure 1). A total of 8 RCTs14-21 met
inclusion criteria for Key Questions 1, 2, and 3 and are sum-
marized in this review. Additionally, we identified one pro-
spective, nonrandomized comparative study22 that satisfied
the inclusion criteria for Key Question 4. Study characteristics,
patient demographics, and detailed results are provided in the
abstraction tables located in the Supplemental Material (avail-
able in the online version of the article).
Our intent was to combine data into a meta-analysis where
possible; however, all comparisons either did not have 2 or more
studies, or the studies were too heterogeneous with regard to
populations, interventions, and/or outcomes to enable pooling.
Key Question 1. What Is the Effectiveness and Safety of
Anticoagulant Thromboprophylaxis Compared to No
Prophylaxis, Placebo, or Another Anticoagulant Strategy
for Preventing DVT and PE After Acute SCI?
Seven RCTs14-17,19,21,23 reported on the efficacy and/or safety
of anticoagulant drug interventions. Two additional studies
claimed randomization but were excluded for the following
reasons: (1) one study24 did not re-randomize patients follow-
ing the acute phase of the trial but rather selected their subjects
based on whether or not they successfully completed the acute
treatment phase; and (2) a second study25 included patients that
were assigned alternately (ie, not randomly) to treatment
groups. The 7 included studies were stratified as follows: (1)
low-molecular-weight heparin (LMWH; enoxaparin) versus no
prophylaxis23; (2) LMWH (enoxaparin) versus LMWH (dalte-
parin)15; (3) fixed-dose versus adjusted-dose unfractionated
heparin (UFH)16; (4) LMWH (tinzaparin and dalteparin) versus
UFH17,21; and (5) UFH versus no treatment or placebo.14,19
LMWH Versus No Prophylaxis. A single RCT compared the effi-
cacy of LMWH versus no anticoagulant prophylaxis. This trial23
reported the risks of DVT and PE in groups that received either
enoxaparin (40mg subcutaneously one time per day for 8 weeks)
or no prophylaxis (both groups had compression stockings).
Patients treated with enoxaparin had a lower rate of DVT
(5.4%) than those who received no LMWH prophylaxis
(21.6%; RD ¼ 16.2, 95% CI ¼ 1.1 to 31.4; RR ¼ 4.0, 95%
CI ¼ 0.91 to 17.6; P ¼ .09). The authors reported a statistically
Figure 1. Study selection flow chart.
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significant difference (P ¼ .04); however, we reanalyzed this
data due to the low number of events using the more conserva-
tive Fisher exact test and found no significant difference. Risk of
PE, bleeding, and mortality were not reported (Table 2).
UFH Versus Placebo or No Treatment. Two RCTs assessed the
risk of DVT in patients receiving UFH (5000 U subcutaneously
every 12 hours14 or every 8 hours19) versus no treatment or
placebo.14,19 The rates of DVT did not significantly differ
between the UFH and the placebo/no prophylaxis groups
(1.8% and 3%, respectively, in one trial14 and 50% and 47%,
respectively, in the other trial19; Table 3).
LMWH Versus LMWH. A single RCT compared the efficacy and
safety of 2 different LMWH drugs. This trial15 reported on the
risks of DVT, PE, bleeding, and mortality in groups that received
either enoxaparin (30mg subcutaneously every 12 hours) or
dalteparin (5000 IU subcutaneously once daily). There was no
statistically significant difference in the rate of DVT between the
enoxaparin and dalteparin groups (6% and 4%, respectively; RD
¼ 1.6, 95% CI ¼ 7.3 to 10.5; RR ¼ 1.35, 95% CI ¼ 0.24 to
7.72; P ¼ 1.0). Furthermore, no patients in either group suffered
a PE. Both treatments were also equally safe: (1) only 1 patient
in the enoxaparin group and 2 patients in the dalteparin group
experienced a bleeding event (RD¼ 2.4, 95% CI¼ 9.6 to 4.7;
RR ¼ 0.45, 95% CI ¼ 0.04 to 4.8; P ¼ .6); and (2) no patients
died in either group (Table 4).
Fixed, Low-Dose UFH Versus Adjusted-Dose UFH. One RCT eval-
uated the efficacy and safety of fixed, low-dose versus
adjusted-dose UFH. This trial16 discussed the risks of DVT,
PE, and bleeding in groups that received either a fixed, low-
dose (initial dose of 5000 U and then 5000 U given subcuta-
neously every 12 hours) or adjusted-dose (initial dose of 5000
U and then adjusted as necessary to keep the activated partial
thromboplastin time value in the 40-50 seconds range) of UFH.
VTE (DVT and/or PE) was seen in 9/29 (31.0%) and 2/29
Table 2. Risks of DVT and PE in Patients With Traumatic Spinal Cord Injury Who Received Enoxaparin Versus No Prophylaxis.
No Prophylaxis, % Patients (n/N) Enoxaparin, % Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Halim (2014) (N ¼ 74) 21.6% (8/37) 5.4% (2/37) 4.0 (0.91 to 17.6) 16.2 (1.1 to 31.4) P ¼ .09
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; PE, pulmonary embolism; RD, risk difference; RR, risk
ratio.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
Table 3. Risks of DVT in Patients With Traumatic Spinal Cord Injury Who Received UFH Versus Placebo/No Prophylaxis.
UFH, % Patients (n/N) Placebo, % Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Agarwal (2009) (N ¼ 297) 1.8% (3/166) 3% (4/131) 0.59 (0.13 to 2.6) 1.2 (2.3 to 4.8) P ¼ .70
Merli (1988) (N ¼ 33) 50% (8/16) 47% (8/17) 1.06 (0.53 to 2.15) 2.9 (31.2 to 37.0) P ¼ 1.0
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; RD, risk difference; RR, risk ratio; UFH, unfractionated
heparin.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
Table 4. Risks of DVT, PE, Bleeding, and Mortality in Patients With Traumatic Spinal Cord Injury Who Received Enoxaparin Versus Dalteparin.
Enoxaparin, % Patients (n/N) Dalteparin, % Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Chiou-Tan (2003) (N ¼ 95) 6% (3/50) 4% (2/45) 1.35 (0.24 to 7.72) 1.6 (7.3 to 10.5) P ¼ 1.0
Risk of PE
Chiou-Tan (2003) (N ¼ 95) 0% (0/50) 0% (0/45) NC 0 P ¼ 1.0
Risk of bleeding
Chiou-Tan (2003) (N ¼ 95) 2% (1/50) 4% (2/45) 0.45 (0.04 to 4.8) 2.4 (9.6 to 4.7) P ¼ .60
Mortality
Chiou-Tan (2003) (N ¼ 95) 0% (0/50) 0% (0/45) NC 0 P ¼ 1.0
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk
difference; RR, risk ratio.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
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(6.9%), respectively (P ¼ .04). The risk of DVT in the fixed,
low-dose group was 3 times greater than the adjusted-dose
group (RD ¼ 13.8, 95% CI ¼ 3.6 to 31.2; RR ¼ 3.0, 95%
CI ¼ 0.66 to 13.7; P ¼ .25; Table 5). Three patients (10.3%) in
the fixed, low-dose group experienced a PE, whereas no
patients in the adjusted group suffered this complication; this
difference did not reach statistical significance (RD ¼ 10.3,
95% CI ¼ 0.7 to 21.4; P ¼ .24). The rate of bleeding was
significantly higher in patients treated with adjusted-dose
heparin (24.1%) than those receiving low-dose (0%; RD ¼
24.1, 95% CI ¼ 8.6 to 39.7; P ¼ .01; Table 5).
LMWH Versus UFH. Two RCTs examined the relative efficacy
and safety of LMWH versus UFH. One trial17 reported on the
risks of DVT, PE, bleeding, and mortality in patients that
received either LMWH (tinzaparin 3500 anti-Xa units given
subcutaneously once daily) or UFH (fixed doses of 5000 U given
subcutaneously every 8 hours). No patients in the LMWH group
experienced a DVT or PE, whereas in the UFH group, 3 (14%)
patients suffered a DVT and 2 (9.5%) a PE; these differences
were not statistically significant for either outcome due to the
low number of events (Table 6). There was a higher rate of
bleeding (9.5%) and mortality (9.5%) in the UFH group
compared to the LMWH group (0% and 0%, respectively),
although these relationships did not reach statistical significance.
A second trial21 also discussed the risks of DVT and PE
events in patients who received either LMWH (dalteparin;
5000 anti-Xa units given subcutaneously once daily) or UFH
(7500 U given subcutaneously twice daily). Similarly, the risks
of DVT (7.5% and 14% for LMWH and UFH, respectively)
and PE (1.25% and 2.3% for LMWH and UFH, respectively)
were lower in the LMWH group than in the UFH group; how-
ever, these differences did not reach statistical significance
(DVT: RD ¼ 6.5, 95% CI ¼ 2.9 to 15.8; RR ¼ 0.54, 95%
CI ¼ 0.21 to 1.4; P ¼ .18; PE: RD ¼ 1.1, 95% CI ¼ 2.9 to
0.05; RR ¼ 0.54, 95% CI ¼ 0.05 to 5.8; P ¼ .60). In this
analysis, we did not pool the data from these 2 studies due to
differences between dalteparin and tinzaparin (Table 6).
Key Question 2. What Is the Comparative Effectiveness
and Safety of Mechanical Strategies Alone or in
Combination With Other Prophylactic Strategies for
Preventing DVT and PE After Acute SCI?
Three RCTs18-20 reported on the efficacy and/or safety of
mechanical strategies alone or in combination with
Table 5. Risks of DVT, PE, and Bleeding in Patients With Traumatic Spinal Cord Injury Who Received Fixed, Low-Dose Heparin Versus
Adjusted-Dose Heparin.
Fixed, Low-Dose Heparin,
% Patients (n/N)
Adjusted-Dose Heparin,
% Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Green (1988) (N ¼ 58) 20.7% (6/29) 6.9% (2/29) 3.0 (0.66 to 13.7) 13.8 (3.6 to 31.2) P ¼ .25
Risk of PE
Green (1988) (N ¼ 58) 10.3% (3/29) 0% (0/29) NC 10.3 (0.7 to 21.4) P ¼ .24
Risk of bleeding
Green (1988) (N ¼ 58) 0% (0/29) 24.1% (7/29) NC 24.1 (8.6 to 39.7) P ¼ .01
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk
difference; RR, risk ratio.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
Table 6. Risks of DVT, PE, Bleeding, and Mortality in Patients With Traumatic Spinal Cord Injury Who Received LMWH Versus UFH.
LMWH, % Patients (n/N) UFH, % Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Green (1990) (N ¼ 41) 0% (0/20) 14.3% (3/21) NC 14.3 (0.7 to 29.3) P ¼ .23
Lohmann (2001) (N ¼ 166) 7.5% (6/80) 14% (12/86) 0.54 (0.21 to 1.4) 6.5 (2.9 to 15.8) P ¼ .18
Risk of PE
Green (1990) (N ¼ 41) 0% (0/20) 9.5% (2/21) NC 9.5 (3.0 to 22.1) P ¼ .49
Lohmann (2001) (N ¼ 166) 1.25% (1/80) 2.3% (2/86) 0.54 (0.05 to 5.8) 1.1 (2.9 to 0.05) P ¼ .60
Risk of bleeding
Green (1990) (N ¼ 41) 0% (0/20) 9.5% (2/21) NC 9.5 (3.0 to 22.1) P ¼ .49
Mortality
Green (1990) (N ¼ 41) 0% (0/20) 9.5% (2/21) NC 9.5 (3.0 to 22.1) P ¼ .49
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; n, number of events; N, total number; NC, not
calculable; PE, pulmonary embolism; RD, risk difference; RR, risk ratio; UFH, unfractionated heparin.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
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antithrombotic drug interventions. The 3 included studies com-
pared the following prophylactic treatments: (1) mechanical
versus mechanical þ antithrombotic drugs18 and (2) anticoa-
gulant versus anticoagulant þ mechanical.19,20
Mechanical Versus Mechanical þ Antithrombotic Drugs. A single
RCT compared the efficacy and safety of mechanical prophy-
laxis versus mechanical prophylaxis plus antithrombotic
drugs.18 This study reported on the risks of DVT and bleeding
in 28 patients who received intermittent pneumatic compres-
sion (IPC) alone and those who were treated with IPC plus
aspirin and dipyridamole (IPC plus aspirin 300mg BID and
dipyridamole 75mg TID). A higher percentage of patients
experienced a DVT in the IPC-only group (40%) than in the
IPC plus aspirin and dipyridamole group (25%); however, this
difference was not statistically significant (RD ¼ 15.0, 95% CI
¼ 19.9 to 49.9; RR ¼ 1.6, 95% CI ¼ 0.50 to 5.10; P ¼ .68).
There was also no difference in safety between treatment
groups: no patients in the IPC group and only one patient in
the IPC plus aspirin and dipyridamole group reported an
adverse bleeding event (RD ¼ 8.3, 95% CI ¼ 7.3 to 24.0;
P ¼ .44; Table 7).
Anticoagulant Versus Anticoagulant þ Mechanical. Two RCTs
compared outcomes between anticoagulant thromboprophy-
laxis and anticoagulant plus mechanical prophylaxis.19,20 The
first trial19 investigated the use of UFH alone (5000 U subcu-
taneously every 8 hours) versus UFH plus electric stimulation
(UFH as described above, plus tibialis anterior and
gastrocnemius-soleus stimulated bilaterally for 23 hours per
day), and a second trial20 compared the use of LMWH (enox-
aparin; 30mg subcutaneously every 12 hours) versus UFH
(5000 U subcutaneously every 8 hours) plus IPC (used at least
22 hours each day). The first trial19 only discussed the risk of
DVT, whereas the other20 reported on rates of DVT, PE, all
VTE, major and minor bleeding, and mortality. Both studies
reported higher risks of DVT in the group that received antic-
oagulant prophylaxis only (50% and 60.3%, respectively) than
in the group that received combined anticoagulant and mechan-
ical intervention (6.7% and 44.9%, respectively; Table 8). In
the trial that compared UFH alone versus UFH plus electric
stimulation,19 the increased risk of DVT in the anticoagulant
prophylaxis group (50%) was nearly 8 times that of the com-
bined treatment group (6.7%; RD ¼ 43.3, 95% CI ¼ 15.8 to
70.9; RR ¼ 7.5, 95% CI ¼ 1.06 to 53.03; P ¼ .02). In the
second trial,20 60.3% of patients treated with LMWH experi-
enced a DVT, whereas only 44.9% of patients who received
UFH plus IPC suffered this adverse event (RD ¼ 15.4, 95% CI
¼ 3.3 to 34.2; RR ¼ 1.34, 95% CI ¼ 0.92 to 1.95; P ¼ .12;
Table 8). The data was not pooled across studies due to differ-
ences in the anticoagulant and mechanical prophylaxis used in
these trials.
In the Spinal Cord Injury Thromboprophylaxis Investigators
(SCITI) trial,20 patients in the LMWH-only group experienced
fewer PE events compared to patients in the UFH plus IPC
group (5.2% and 18.4%, respectively); this difference was
nearly statistically significant (RD ¼ 13.2, 95% CI ¼ 0.9 to
25.4; RR ¼ 0.28, 95% CI ¼ 0.08 to 0.98; P ¼ .06). The risk of
all VTE, major and minor bleeding, and mortality were similar
between groups (Table 8).
Key Question 3. What Is the Comparative Effectiveness
and Safety of Prophylactic IVC Filter Insertion Alone or in
Combination With Other Prophylactic Strategies for
Preventing DVT and PE After Acute SCI?
We did not identify any RCTs that met our inclusion criteria for
this key question.
Key Question 4. What Is the Optimal Timing to Initiate
and/or Discontinue Anticoagulant, Mechanical, and/or
Prophylactic IVC Filter Following Acute SCI?
One prospective, non-RCT22 examined the timing of initiation
of anticoagulant thromboprophylaxis in patients with acute
SCI. This study reported on the risks of DVT and PE in patients
that received prophylaxis initiated within (early group) or after
(late group) 72 hours of injury. The prophylactic protocol con-
sisted of LMWH (nadroparin; 0.4mL once per day) plus early
mobilization, graduated compression stockings (GCS), and IPC
devices (3 hours per day given in 2 applications) for the lower
limbs. The number of patients who suffered a DVT was sig-
nificantly lower in the early group (n ¼ 2) compared to the late
Table 7. Risks of DVT and Bleeding in Patients With Traumatic Spinal Cord Injury Who Received Mechanical Prophylaxis Alone Versus
Mechanical Plus Anticoagulant Prophylaxis.
IPC, % Patients
(n/N)
IPC þ Aspirin þ Dipyridamole,
% Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Green (1982) (N ¼ 27) 40% (6/15) 25% (3/12) 1.6 (0.50 to 5.10) 15.0 (19.9 to 49.9) P ¼ .68
Risk of bleeding
Green (1982) (N ¼ 27) 0% (0/15) 8.3% (1/12) NC 8.3 (7.3 to 24.0) P ¼ .44
Abbreviations: CI, confidence interval; IPC, intermittent pneumatic compression; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not
calculable; RD, risk difference; RR, risk ratio.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
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group (n ¼ 46; RD ¼ 24.1, 95% CI ¼ 17.1 to 31.2; RR ¼ 12.9,
95% CI ¼ 3.2 to 51.2; P < .001; Table 9). No patients in either
group experienced a PE event. Safety outcomes were not
reported in this study.
Key Question 5. What Is the Cost-Effectiveness of the
Treatment Options Evaluated in Key Questions 1 to 4?
We did not identify any studies that met our inclusion criteria
for this Key Question.
Strength of Evidence Summary
See the Supplemental Material for detailed tables (available in
the online version of the article).
Key Question 1. What is the effectiveness and safety of
anticoagulant thromboprophylaxis compared to no prophylaxis,
placebo, or another anticoagulant strategy for preventing DVT and
PE after acute SCI?
Overall, the strength of evidence was low for evaluating the
comparative efficacy and safety of various anticoagulant pro-
phylactic strategies (eg, enoxaparin, dalteparin, tinzaparin,
UFH) in patients with acute SCI. The strength of evidence was
moderate for comparing the efficacy and safety of fixed, low-
dose versus adjusted-dose UFH.
LMWH versus no prophylaxis. There is low-quality evidence
that the risk of DVT (but not PE) is higher in patients who
received no prophylaxis compared to those who received
LMWH (enoxaparin). The risk of DVT was 4 times greater
in patients treated without prophylaxis; however, this did not
quite reach statistical significance in our conservative analysis
(Table 10).
UFH versus placebo or no treatment. There is low-quality
evidence that there is no difference in the risk of DVT in
patients treated with either UFH or placebo/no prophylaxis
(Table 10).
Table 9. Risks of DVT and PE in Patients With Traumatic Spinal Cord Injury Who Received Early (72 Hours) Versus Late (>72 Hours)
Prophylaxis.
Early (72 Hours),
% Patients (n/N)
Late (>72 Hours),
% Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Aito (2002) (N ¼ 275) 2% (2/99) 26% (46/176) 12.9 (3.2 to 51.2) 24.1 (17.1 to 31.2) P < .001
Risk of PE
Aito (2002) (N ¼ 275) 0% (0/99) 0% (0/176) NC 0 P ¼ 1.0
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; NC, not calculable; PE, pulmonary embolism; RD, risk
difference; RR, risk ratio.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
Table 8. Risks of DVT, PE, All VTE, Major Bleeding, Minor Bleeding, and Mortality in Patients With Traumatic Spinal Cord InjuryWho Received
Anticoagulant Prophylaxis Alone Versus Anticoagulant Plus Mechanical Prophylaxis.
Anticoagulant,
% Patients (n/N)
Anticoagulant þ Mechanical,
% Patients (n/N) RR (95% CI)a RD (95% CI)a P Valueb
Risk of DVT
Merli (1988) (N ¼ 31) 50% (8/16) 6.7% (1/15) 7.5 (1.06 to 53.03) 43.3 (15.8 to 70.9) P ¼ .02
SCITIc (2003) (N ¼ 107) 60.3% (35/58) 44.9% (22/49) 1.34 (0.92 to 1.95) 15.4 (3.3 to 34.2) P ¼ .12
Risk of PE
SCITIc (2003) (N ¼ 107) 5.2% (3/58) 18.4% (9/49) 0.28 (0.08 to 0.98) 13.2 (0.9 to 25.4) P ¼ .06
Risk of all VTE
SCITIc (2003) (N ¼ 107) 65.5% (38/58) 63.3% (31/49) 1.04 (0.78 to 1.38) 2.3 (16.0 to 20.5) P ¼ .84
Risk of major bleeding
SCITI (2003) (N ¼ 476) 2.6% (6/230) 5.3% (13/246) 0.49 (0.19 to 1.28) 2.7 (0.8 to 6.1) P ¼ .16
Risk of minor bleeding
SCITI (2003) (N ¼ 476) 14.8% (34/230) 17.9% (44/246) 0.83 (0.55 to 1.25) 3.1 (3.5 to 9.7) P ¼ .39
Mortality
SCITI (2003) (N ¼ 476) 0.9% (2/230) 0.8% (2/246) 1.07 (0.15 to 7.53) 0.1 (1.5 to 2.5) P ¼ 1.0
Abbreviations: CI, confidence interval; DVT, deep vein thrombosis; n, number of events; N, total number; PE, pulmonary embolism; RD, risk difference; RR, risk
ratio; VTE, venous thromboembolism.
aCalculated from data provided by authors of primary studies.
bP value calculated using Fisher exact test.
cPatients with adequate proximal and distal diagnostic imaging or evidence of PE.
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LMWH versus LMWH. There is low-quality evidence that
there is no difference in the risks of DVT, PE, bleeding, or
mortality between patients administered with enoxaparin and
those treated with dalteparin (Table 10).
LMWH versus UFH. There is low-quality evidence that there
is no difference in the risks of DVT, PE, bleeding, or mortality
in patients who received either LMWH (tinzaparin or dalte-
parin) or UFH (Table 10).
Fixed, low-dose UFH versus adjusted-dose UFH. There is low-
quality evidence that the risk of DVT (but not PE) is higher in
patients who received fixed, low-dose heparin compared to
those treated with adjusted-dose heparin. There is moderate
quality evidence that patients administered with fixed, low-
dose heparin have a lower risk of bleeding than those who
received an adjusted-dose (Table 10).
Key Question 2. What is the comparative effectiveness and safety of
mechanical strategies alone or in combination with other
prophylactic strategies for preventing DVT and PE after acute SCI?
Overall, the strength of evidence was low for evaluating the
comparative efficacy and safety of mechanical prophylactic
strategies (eg, IPC, electric calf stimulation) alone or in com-
bination with other prophylactic strategies (eg, UFH, aspirin).
Mechanical versus mechanical þ anticoagulant. There is low-
quality evidence to suggest that there is no difference in the risk
of DVT or bleeding between patients receiving IPC alone ver-
sus IPC plus aspirin and dipyridamole (Table 11).
Anticoagulant versus anticoagulantþmechanical. There is low-
quality evidence that patients who received a combination of
UFH and electric calf stimulation have a lower risk of DVT
than patients treated with UFH alone. There is low-quality
evidence that there is no difference in the risk of DVT in
patients who received LMWH alone compared to those
treated with UFH plus IPC. There is low-quality evidence that
patients administered with LMWH alone have a lower risk of
PE compared with patients who received UFH plus IPC.
Based on low-quality evidence, there is also no difference
in the risks of VTE, major and minor bleeding, and mortality
between patients who received LMWH and those treated with
UFH plus IPC (Table 11).
Key Question 3: What is the comparative effectiveness and safety of
prophylactic IVC filter alone or in combination with other
Table 10. Summary GRADE Table for Key Question 1: What Is the Effectiveness and Safety of Anticoagulant Thromboprophylaxis Compared
to No Prophylaxis, Placebo, or Another Anticoagulant Strategy for Preventing DVT and PE After Acute Spinal Cord Injury?
Comparisons
Number of
Studies (N)
Strength of
Evidence Grade Conclusions, Effect Size
Enoxaparin vs No
prophylaxis
1 RCT (N ¼ 74) (Halim, 2014) Low Based on a single RCT, patients treated with enoxaparin had a
lower rate of DVT (5.4%) than those who received no
anticoagulant prophylaxis (21.6%), although this relationship did
not reach statistical significance using the conservative Fisher
exact test. There were no observed PE events in either group.
Bleeding and mortality were not reported.
UFH vs No
treatment or
Placebo
1 RCT (N ¼ 297) (Agarwal, 2009)
1 RCT (N ¼ 33) (Merli, 1988)
Low Based on 2 RCTs, rates of DVT did not significantly differ between
the UFH and the placebo/no prophylaxis group (1.8% and 3% in
one trial and 50% and 47% in the other trial).
Enoxaparin vs
Dalteparin
1 RCT (N ¼ 95) (Chiou-Tan, 2003) Low Based on a single small RCT, there were no statistically significant
differences in the rate of DVT between the enoxaparin and
dalteparin groups. No patients in either group suffered a PE.
There were also no differences between the groups with
respect to safety.
Fixed, low-dose vs
Adjusted-dose
heparin
1 RCT (N ¼ 58) (Green, 1988) Low The risks of DVT and PE were greater in the fixed, low-dose group
(20.7% and 6.9%, respectively) than in the adjusted-dose group
(10% and 0%, respectively). These relationships were not
statistically significant due to low event rates.
Moderate The rate of bleeding was significantly higher in patients treated
with adjusted-dose heparin (24.1%) than those receiving low-
dose heparin (0%).
LMWH vs UFH
Tinzaparin vs
UFH
1 RCT (N ¼ 41) (Green, 1990) Low Based on 2 RCTs, there were no significant differences in risk of
DVT, PE, bleeding or mortality between patients treated with
LMWH versus UFH. The number of events were very small in
both groups.
Dalteparin vs
UFH
1 RCT (N ¼ 166) (Lohmann, 2001)
Abbreviations: DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized controlled trial; UFH, unfractio-
nated heparin.
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prophylactic strategies for preventing DVT and PE after acute SCI?
We did not identify any studies that met our inclusion criteria.
There is therefore insufficient evidence to answer this key
question.
Key Question 4. What is the optimal timing to initiate and/or
discontinue anticoagulant, mechanical and/or prophylactic IVC
filter following acute SCI?
There is low-quality evidence that the risk of DVT is signifi-
cantly lower in patients receiving prophylaxis within 72 hours
than those treated after 72 hours of injury. The prophylactic
treatment protocol in this study was LMWH plus early mobi-
lization, GCS, and IPC of the lower limbs. The level of evi-
dence was upgraded from insufficient due to the strong
magnitude of effect. There is no difference between these
groups regarding the risk of PE; however, the evidence for this
conclusion is insufficient (Table 12).
Key Question 5. What is the cost-effectiveness of the treatment
options evaluated in Key Questions 1 to 4?
We did not identify any studies that met our inclusion criteria.
There is therefore insufficient evidence to answer this key
question.
Discussion
SCI is associated with an increased risk of VTE due to neuro-
logic dysfunction, immobilization, and hypercoagulability.1
These patients experience extensive tissue damage and are
commonly treated with invasive surgical procedures. As a
result, there is a fear of hemorrhage or bleeding, particularly
around neural tissues where a minor hematoma can have devas-
tating consequences such as paralysis. Surgeons must imple-
ment appropriate anticoagulation strategies to reduce the risk of
DVT and PE without increasing the risk of hemorrhagic
complications. This review compared the efficacy and safety of
various prophylactic treatment protocols, including antithrombo-
tic drugs, mechanical strategies, and prophylactic IVC filter.
Antithrombotic Drug Strategies
Antithrombotic drugs for DVT and PE prophylaxis target the
coagulation cascade. Halim et al reported that patients who did
not receive any active thromboprophylaxis were at 4 times higher
risk of DVT than those treated with LMWH (enoxaparin).23 In
Table 12. Summary GRADE Table for Key Question 4: What Is the
Optimal Timing to Initiate and/or Discontinue Anticoagulant,
Mechanical, and/or Prophylactic IVC Filter Following Acute Spinal
Cord Injury?
Comparisons
Number of
Studies (N)
Strength of
Evidence
Grade
Conclusions,
Effect Size
72 hours vs >72
hours: LMWH þ
Early mobilization
þ Compression
stockings þ IPC
1 RCT (N
¼ 275)
(Aito,
2002)
Low The number of
patients who
suffered a DVT
was significantly
lower in the early
intervention group
(n ¼ 2) compared
to the late group
(n ¼ 46).
Insufficienta No PE events were
observed.
Abbreviations: DVT, deep vein thrombosis; IPC, intermittent pneumatic com-
pression; LMWH, low-molecular-weight heparin; PE, pulmonary embolism;
RCT, randomized controlled trial.
aConclusions are not possible due to study limitations (ie, methodology), small
sample sizes resulting in low precision of estimates, and/or limited data from
single studies.
Table 11. Summary GRADE Table for Key Question 2: What Is the Comparative Effectiveness and Safety of Mechanical Strategies Alone or in
Combination With Other Prophylactic Strategies for Preventing DVT and PE After Acute Spinal Cord Injury?
Comparisons
Number of
Studies (N)
Strength of
Evidence Grade Conclusions, Effect Size
Mechanical vs Mechanical þ Anticoagulant
IPC only vs IPC þ Aspirin
þ Dipyridamole
1 RCT (N ¼ 27)
(Green, 1982)
Low A higher percentage of patients experienced a DVT in the IPC only group
(40%) than in the IPC plus aspirin and dipyridamole group (25%);
however, this difference was not statistically significant. There was also
no difference in rates of bleeding between groups.
Mechanical þ Anticoagulant vs anticoagulant
UFH þ Electric calf
stimulation vs UFH
1 RCT (N ¼ 31)
(Merli, 1988)
Low Based on a single RCT, the increased risk of DVT in the anticoagulant
prophylaxis group (50%) was nearly 8 times that of the combined
treatment group (6.7%).
UFH þ IPC vs LMWH 1 RCT (N ¼ 107)
(SCITI, 2003)
In a second RCT, 60.3% of patients treated with LMWH experienced a
DVT, whereas 44.9% of patients who received UFH plus IPC suffered
this complication (not statistically significant). The risk of PE was higher
in the UFH þ IPC group (18.4%) compared to the LMWH group (5.2%).
The risks of all VTE, major and minor bleeding, and mortality were
similar between groups.
Abbreviations: DVT, deep vein thrombosis; IPC, intermittent pneumatic compression; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT,
randomized controlled trial; UFH, unfractionated heparin; VTE, venous thromboembolic event.
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their study, this relative risk was reported as statistically sig-
nificant. In our systematic review, however, we reanalyzed
their data using the conservative Fisher exact test due to the
low number of events; the comparison between groups
approached but did not reach statistical significance. Thus,
although this conclusion agrees with clinical observations that
anticoagulant thromboprophylaxis is superior to no treatment
for preventing DVT, more definitive evidence is required.
In this review, several studies evaluated the relative efficacy
and safety of various anticoagulant strategies, including enox-
aparin versus dalteparin,15 fixed- versus adjusted-dose UFH,16
and UFH versus LMWH.17,21 There was no statistically signif-
icant difference in the efficacy or safety between 2 types of
LMWH, enoxaparin (30mg subcutaneously every 12 hours) or
dalteparin (5000 IU subcutaneously once daily); however, only
95 patients were evaluated.
In a study by Green et al, the risk of DVT in patients treated
with fixed, low-dose UFH was nearly 3 times greater than in
patients receiving an adjusted dose.16 Although this conclusion
might suggest that adjusted-dose UFH is a superior therapy,
this relationship did not reach statistical significance and the
rate of adverse bleeding events was significantly higher than in
the fixed, low-dose group. Given that patients with SCI are
often managed surgically, anticoagulant doses that cause
excessive bleeding should be avoided.
There was a tendency for reduced risk of DVT and PE in
patients receiving LMWH compared to those treated with
UFH.17 Low event rates in both groups, however, prevented
definitive conclusions from being made. Furthermore, there
were no statistically significant differences in rates of bleeding
or mortality between prophylactic treatment groups. Other fac-
tors may also be considered when devising an appropriate treat-
ment protocol, including cost and heparin-induced
thrombocytopenia. LMWH is typically a more expensive ther-
apy than UFH treatment. Patients treated with UFH, however,
also have a much higher incidence of heparin-induced throm-
bocytopenia (2.6%) compared to users of LMWH (0.2%).26
Combined Strategies
Green et al compared the risks of DVT and bleeding in patients
who received mechanical prophylaxis alone or in combination
with an antiplatelet strategy.18 Based on their results, there was a
higher rate of DVT in the IPC-only group (40%) than in the IPC
plus aspirin and dipyridamole group (25%); however, this dif-
ference was not statistically significant. Mechanical prophylaxis,
in combination with antithrombotic drug strategies, may work
synergistically to reduce the risk of DVT. There was no signif-
icant difference in risk of bleeding between treatment groups.
Two other studies evaluated the relative efficacy and safety
of anticoagulant thromboprophylaxis versus combined antic-
oagulant and mechanical strategies.19,20 Merli et al reported a
significantly reduced risk of DVT in patients who received
UFH plus electric calf stimulation compared to those treated
with only UFH.19 This result indicates that DVT may be best
prevented through combined strategies that reduce stasis as
well as hypercoagulability. Furthermore, electric calf stimula-
tion may decrease stasis better than IPC as it compresses the
calf muscle at a greater frequency.19
The SCITI trial compared the risk of DVT, PE, major and
minor bleeding, and mortality between patients treated with
LMWH and those who received a combination of UFH and
IPC.20 Rates of all VTE were similar between groups, 63%
versus 66%, respectively. There was a trend toward a lower
rate of DVT in the UFH plus IPC group (44.9%) compared with
the LMWH group (60.3%), while the rate of PE was higher in
the combined anticoagulant and mechanical prophylaxis group.
The risk of major and minor bleeding and mortality did not
differ between treatment groups.
Prophylactic IVC Filter Strategies
No studies evaluated the efficacy and safety of prophylactic
IVC filters in patients with traumatic SCI. In a study by
McClendon et al, the use of prophylactic IVC filters reduced
the odds of developing a PE in patients undergoing major
spinal reconstructive surgery compared to population
controls.27 Furthermore, Rodriguez et al reported a signifi-
cantly decreased incidence of PE in patients at a high risk of
this complication.28 However, in a retrospective study of
54 SCI patients, the insertion of a prophylactic IVC filter
increased the risk of DVT compared to a control group despite
the routine use of anticoagulant thromboprophylaxis.29 Further
research is needed to confirm the efficacy and safety of pro-
phylactic IVC filters in patients with SCI.
Timing of Prophylaxis
Spine surgeons must determine the ideal timing to initiate
anticoagulant thromboprophylaxis in patients with either iso-
lated SCI or with other additional traumatic injuries. These
decisions must balance the need to prevent DVT and PE with
the risk of increased bleeding. In a study by Aito et al, the risk
of DVT was 13 times greater if prophylaxis (anticoagulant with
mechanical) was employed >72 hours after injury compared to
within 72 hours of injury.22 There were no PE events reported
in either group. Patients can generally be started on anticoagu-
lant therapies within 72 hours to decrease the risk of DVT.
Cost-Effectiveness
No studies specifically analyzed the cost-effectiveness of DVT/
PE prophylaxis in the traumatic SCI population. In patients
with acute ischemic stroke, however, Pineo et al reported a
lower average anticoagulant cost, including drug-
administration costs, in patients treated with UFH ($259) com-
pared to those who received LMWH ($360).30 In contrast, total
hospital costs, including both clinical events and drug costs,
were lower in the LMWH group ($782) than in the UFH group
($922). In the traumatic SCI population, there is limited data to
suggest superior outcomes of one treatment over another; as a
result, direct drug and administration costs may have a larger
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impact on decision making. Future cost-effectiveness studies
are required to confirm this hypothesis and must consider costs
associated with length of stay, adverse events, and drug
administration.
Strengths and Limitations
The strength of this systematic review is that it primarily sum-
marizes results from RCTs. Furthermore, studies in all lan-
guages were considered for inclusion.
The limitations of this review include (1) poor methodologic
quality of included studies, (2) small sample sizes and low
event rates, and (3) significant clinical heterogeneity across
studies prevented data pooling and meta-analysis (eg, differ-
ences in populations, antithrombotic drug and mechanical
treatment protocols, diagnostic methods and outcomes).
Conclusions
Prophylactic treatments can be used to lower the risk of VTE
events in patients with acute SCI, without significant increase
in risk of bleeding and mortality. There were no significant
differences in efficacy and safety of different types of LMWH
or between LMWH and UFH. Patients should not be treated
with adjusted-dose heparin due to significantly a higher risk of
bleeding. Prophylaxis should generally be initiated as early as
is safe after injury.
Acknowledgments
We would like to acknowledge Dr William Geerts for his thorough
external review of this systematic review. We would also like thank
Jeffrey Hermsmeyer, BS, for his assistance with literature searching,
data abstraction, and critical appraisal of included studies.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
research was supported by AOSpine and the AANS/CNS Section
on Neurotrauma and Critical Care. Dr Fehlings wishes to acknowledge
support from the Gerald and Tootsie Halbert Chair in Neural Repair
and Regeneration and the DeZwirek Family Foundation. Dr Tetreault
acknowledges support from a Krembil Postdoctoral Fellowship
Award. Analytic support for this work was provided by Spectrum
Research, Inc, with funding from the AOSpine North America.
Supplemental Material
The supplemental material is available in the online version of the
article.
References
1. Teasell RW, Hsieh JT, Aubut JA, et al. Venous thromboembolism
after spinal cord injury. Arch Phys Med Rehabil. 2009;90:
232-245. doi:10.1016/j.apmr.2008.09.557.
2. Miranda AR, Hassouna HI. Mechanisms of thrombosis in spinal
cord injury. Hematol Oncol Clin North Am. 2000;14:401-416.
3. Cheng JS, Arnold PM, Anderson PA, Fischer D, Dettori JR. Antic-
oagulation risk in spine surgery. Spine (Phila Pa 1976). 2010;
35(9 suppl):S117-S124. doi:10.1097/BRS.0b013e3181d833d4.
4. Gerlach R, Raabe A, Beck J, Woszczyk A, Seifert V. Postopera-
tive nadroparin administration for prophylaxis of thromboembolic
events is not associated with an increased risk of hemorrhage after
spinal surgery. Eur Spine J. 2004;13:9-13. doi:10.1007/s00586-
003-0642-8.
5. Fehlings MG, Wilson JR, Kopjar B, et al. Efficacy and safety of
surgical decompression in patients with cervical spondylotic mye-
lopathy: results of the AOSpine North America prospective multi-
center study. J Bone Joint Surg Am. 2013;95:1651-1658. doi:10.
2106/JBJS.L.00589.
6. Wright JG, Swiontkowski MF, Heckman JD. Introducing lev-
els of evidence to the journal. J Bone Joint Surg Am. 2003;85-
A:1-3.
7. Skelly AC, Hashimoto RE, Norvell DC, et al. Cervical
spondylotic myelopathy: methodological approaches to eval-
uate the literature and establish best evidence. Spine (Phila
Pa 1976). 2013;38(22 suppl 1):S9-S18. doi:10.1097/BRS.
0b013e3182a7ebbf.
8. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and
strength of recommendations. BMJ. 2004;328:1490.
9. Balshem H, Helfand M, Schunemann HJ, et al. GRADE guide-
lines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;
64:401-406.
10. Northover JR, Wild JB, Braybrooke J, Blanco J. The epidemiol-
ogy of cervical spondylotic myelopathy. Skeletal Radiol. 2012;
41:1543-1546. doi:10.1007/s00256-012-1388-3.
11. West S, King V, Carey TS, et al. Systems to Rate the Strength of
Scientific Evidence (Evidence Report/Technology Assessment
No. 47). Rockville, MD: Agency for Healthcare Research and
Quality; 2002.
12. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5:
grading the strength of a body of evidence when comparing med-
ical interventions—Agency for Healthcare Research and Quality
and the Effective Health-Care Program. J Clin Epidemiol. 2010;
63:513-523. doi:10.1016/j.jclinepi.2009.03.009.
13. StataCorp. Stata Statistical Software: Release 9. College Station,
TX: StataCorp LP; 2005.
14. Agarwal NK, Mathur N. Deep vein thrombosis in acute spinal
cord injury. Spinal Cord. 2009;47:769-772.
15. Chiou-Tan FY, Garza H, Chan KT, et al. Comparison of dalte-
parin and enoxaparin for deep venous thrombosis prophylaxis in
patients with spinal cord injury. Am J Phys Med Rehabil. 2003;82:
678-685.
16. Green D, Lee MY, Ito VY, et al. Fixed- vs adjusted-dose heparin
in the prophylaxis of thromboembolism in spinal cord injury.
JAMA. 1988;260:1255-1258.
17. Green D, Lee MY, Lim AC, et al. Prevention of thromboembo-
lism after spinal cord injury using low-molecular-weight heparin.
Ann Intern Med. 1990;113:571-574.
18. Green D, Rossi EC, Yao JS, Flinn WR, Spies SM. Deep vein
thrombosis in spinal cord injury: effect of prophylaxis with calf
Arnold et al 149S
compression, aspirin, and dipyridamole. Paraplegia. 1982;20:
227-234.
19. Merli GJ, Herbison GJ, Ditunno JF, et al. Deep vein thrombosis:
prophylaxis in acute spinal cord injured patients. Arch Phys Med
Rehabil. 1988;69:661-664.
20. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention
of venous thromboembolism in the acute treatment phase after
spinal cord injury: a randomized, multicenter trial comparing low-
dose heparin plus intermittent pneumatic compression with enox-
aparin. J Trauma. 2003;54:1116-1124.
21. Lohmann U, Glaser E, Braun BE, Botel U. Prevention of throm-
boembolism in spinal fractures with spinal cord injuries. Standard
heparin versus low-molecular-weight heparin in acute paraplegia
[in German]. Zentralbl Chir. 2001;126:385-390. doi:10.1055/s-
2001-14757.
22. Aito S, Pieri A, D’Andrea M, Marcelli F, Cominelli E. Primary
prevention of deep venous thrombosis and pulmonary embolism
in acute spinal cord injured patients. Spinal Cord. 2002;40:
300-303.
23. Halim TA, Chhabra HS, Arora M, Kumar S. Pharmacological
prophylaxis for deep vein thrombosis in acute spinal cord injury:
an Indian perspective. Spinal Cord. 2014;52:547-550. doi:10.
1038/sc.2014.71.
24. Spinal Cord Injury Thromboprophylaxis Investigators. Prevention
of venous thromboembolism in the rehabilitation phase after
spinal cord injury: prophylaxis with low-dose heparin or enoxa-
parin. J Trauma. 2003;54:1111-1115.
25. Frisbie JH, Sasahara AA. Low dose heparin prophylaxis for deep
venous thrombosis in acute spinal cord injury patients: a con-
trolled study. Paraplegia. 1981;19:343-346.
26. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocy-
topenia with unfractionated and low-molecular-weight heparin
thromboprophylaxis: a meta-analysis. Blood. 2005;106:
2710-2715. doi:10.1182/blood-2005-04-1546.
27. McClendon J Jr, O’Shaughnessy BA, Smith TR, et al. Compre-
hensive assessment of prophylactic preoperative inferior vena cava
filters for major spinal reconstruction in adults. Spine (Phila Pa
1976). 2012;37:1122-1129. doi:10.1097/BRS.0b013e31824abde2.
28. Rodriguez JL, Lopez JM, Proctor MC, et al. Early placement of
prophylactic vena caval filters in injured patients at high risk for
pulmonary embolism. J Trauma. 1996;40:797-802.
29. Gorman PH, Qadri SF, Rao-Patel A. Prophylactic inferior vena
cava (IVC) filter placement may increase the relative risk of deep
venous thrombosis after acute spinal cord injury. J Trauma. 2009;
66:707-712. doi:10.1097/TA.0b013e318188beba.
30. Pineo G, Lin J, Stern L, Subrahmanian T, Annemans L. Economic
impact of enoxaparin versus unfractionated heparin for venous
thromboembolism prophylaxis in patients with acute ischemic
stroke: a hospital perspective of the PREVAIL trial. J Hosp Med.
2012;7:176-182. doi:10.1002/jhm.968.
150S Global Spine Journal 7(3S)
